Siemens revenue falls 7% in third quarter
August 3, 2020 -- Siemens Healthineers saw its revenue fall 7% in the company's third fiscal quarter due to the impact of the COVID-19 pandemic. The company saw a single-digit sales decline in its Imaging business and a double-digit drop in its Diagnostics division.
NanoString launches readout technology for NGS
August 3, 2020 -- NanoString Technologies released Cancer Transcriptome Atlas, a new product based on the company's GeoMx digital spatial profiler platform that's optimized for readout on Illumina's next-generation sequencing (NGS) technology.
FDA clears EUA change for Applied DNA coronavirus test
August 3, 2020 -- Applied DNA Sciences announced that the U.S. Food and Drug Administration (FDA) has granted an emergency use authorization (EUA) amendment for its Linea COVID-19 assay kit, a change that it says could boost throughput in labs.
NIH invests almost $249M in 7 COVID-19 test technologies
July 31, 2020 -- The U.S. National Institutes of Health (NIH) is touting the results of its "Shark Tank" approach to spurring development in COVID-19 testing technologies, with $248.7 million invested in a variety of different methods that promise rapid results.
COVID-19 spurs Q2 sales boom at Quidel
July 31, 2020 -- Quidel announced that revenue in its second quarter has skyrocketed due to sales of COVID-19 tests.
LabCorp to offer total COVID-19 antibody testing for free
July 31, 2020 -- LabCorp plans to offer total antibody testing at no charge through patients' doctors in support of increased blood plasma donations for use as a possible COVID-19 treatment.
Bio-Rad's Q2 revenue drops
July 31, 2020 -- Bio-Rad Laboratories reported that the COVID-19 pandemic negatively impacted its revenue for the second quarter as well as for the first half of the year.
ACS cervical cancer guidelines disappoint some testing firms
July 31, 2020 -- Diagnostics developer Hologic has voiced disappointment with new cervical cancer screening guidelines from the American Cancer Society (ACS).
PanCan, GeneCentric partner on precision medicine for pancreatic cancer
July 31, 2020 -- The Pancreatic Cancer Action Network (PanCan) and GeneCentric Therapeutics have partnered to conduct research on RNA-based molecular technologies to predict pancreatic cancer disease progression and drug response.
Medicare to pay for Myriad's BRCA testing in prostate cancer patients
July 31, 2020 -- Medicare will be covering use of Myriad's BracAnalysis companion diagnostic in men with prostate cancer who may be eligible for treatment with the poly (ADP-ribose) polymerase inhibitor olaparib (Lynparza).